Last $4.62 USD
Change Today +0.07 / 1.54%
Volume 3.6M
ARNA On Other Exchanges
As of 4:30 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (ARNA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/14 - $7.38
52 Week Low
10/13/14 - $3.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

arena pharmaceuticals inc (ARNA) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (ARNA) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company’s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

310 Employees
Last Reported Date: 03/3/14
Founded in 1997

arena pharmaceuticals inc (ARNA) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $725.0K
Co-Founder, Executive Vice President, Chief S...
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $395.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

arena pharmaceuticals inc (ARNA) Key Developments

Arena Pharmaceuticals Seeks Acquisitions

Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) has filed a Follow-on Equity Offering. Arena Pharmaceuticals will use a portion of the net proceeds to acquire drugs or drug candidates, technologies, businesses or other assets.

Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension

Arena Pharmaceuticals, Inc. announced the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). This 22-week, randomized, double-blind and placebo-controlled Phase 2 trial will evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag in up to 60 patients with PAH. During the first nine weeks of the trial, patients will be titrated to their individual tolerance level, and then sustained at this level for the remainder of the trial.

Arena Pharmaceuticals Reports Positive Results from Phase 1B Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

Arena Pharmaceuticals, Inc. announced results from a phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. In the phase 1b clinical trial, APD334 demonstrated a dose-dependent effect on lymphocyte count lowering in blood, with mean decreases from baseline of up to 69%. Lymphocyte counts, on average, recovered to baseline within one week of conclusion of dosing. There were no clinically significant safety findings with respect to heart rate or rhythm or pulmonary function, and no clinically significant elevations in liver enzyme tests. The most common treatment-emergent adverse events were mild or moderate contact dermatitis, headache, constipation and diarrhea, with none being clearly drug related. There were no discontinuations for adverse events, and no serious adverse events were observed. The randomized, double-blind, placebo-controlled Phase 1b clinical trial evaluated the safety, tolerability, pharmacodynamics and pharmacokinetics of multiple-ascending doses of APD334. In five different dosing cohorts, a total of 50 healthy volunteers received APD334 and 10 received placebo for 21 days.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNA:US $4.62 USD +0.07

ARNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.37 USD +0.27
Array BioPharma Inc $7.81 USD +0.70
Progenics Pharmaceuticals Inc $6.36 USD +0.22
Rigel Pharmaceuticals Inc $2.21 USD +0.07
Spectrum Pharmaceuticals Inc $6.91 USD +0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation ARNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.2x
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at